Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

S. A. Rosenberg, B. S. Packard, P. M. Aebersold, D. Solomon, Suzanne Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, C. Simpson, C. Carter, S. Bock, D. Schwartzentruber, J. P. Wei, D. E. White

Research output: Contribution to journalArticle

Abstract

Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive tranfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.

Original languageEnglish (US)
Pages (from-to)1676-1680
Number of pages5
JournalNew England Journal of Medicine
Volume319
Issue number25
StatePublished - 1988
Externally publishedYes

Fingerprint

Immunotherapy
Interleukin-2
Melanoma
Neoplasms
Tumor-Infiltrating Lymphocytes
Lymphokine-Activated Killer Cells
Experimental Melanomas
Poisons
Cyclophosphamide
Therapeutics
Lymphocytes
Bone and Bones
Lung
Skin
Survival
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S., Toy, S. T., ... White, D. E. (1988). Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New England Journal of Medicine, 319(25), 1676-1680.

Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. / Rosenberg, S. A.; Packard, B. S.; Aebersold, P. M.; Solomon, D.; Topalian, Suzanne; Toy, S. T.; Simon, P.; Lotze, M. T.; Yang, J. C.; Seipp, C. A.; Simpson, C.; Carter, C.; Bock, S.; Schwartzentruber, D.; Wei, J. P.; White, D. E.

In: New England Journal of Medicine, Vol. 319, No. 25, 1988, p. 1676-1680.

Research output: Contribution to journalArticle

Rosenberg, SA, Packard, BS, Aebersold, PM, Solomon, D, Topalian, S, Toy, ST, Simon, P, Lotze, MT, Yang, JC, Seipp, CA, Simpson, C, Carter, C, Bock, S, Schwartzentruber, D, Wei, JP & White, DE 1988, 'Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report', New England Journal of Medicine, vol. 319, no. 25, pp. 1676-1680.
Rosenberg, S. A. ; Packard, B. S. ; Aebersold, P. M. ; Solomon, D. ; Topalian, Suzanne ; Toy, S. T. ; Simon, P. ; Lotze, M. T. ; Yang, J. C. ; Seipp, C. A. ; Simpson, C. ; Carter, C. ; Bock, S. ; Schwartzentruber, D. ; Wei, J. P. ; White, D. E. / Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. In: New England Journal of Medicine. 1988 ; Vol. 319, No. 25. pp. 1676-1680.
@article{36faf44e122248929cbd740557de9d15,
title = "Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report",
abstract = "Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive tranfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.",
author = "Rosenberg, {S. A.} and Packard, {B. S.} and Aebersold, {P. M.} and D. Solomon and Suzanne Topalian and Toy, {S. T.} and P. Simon and Lotze, {M. T.} and Yang, {J. C.} and Seipp, {C. A.} and C. Simpson and C. Carter and S. Bock and D. Schwartzentruber and Wei, {J. P.} and White, {D. E.}",
year = "1988",
language = "English (US)",
volume = "319",
pages = "1676--1680",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "25",

}

TY - JOUR

T1 - Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

AU - Rosenberg, S. A.

AU - Packard, B. S.

AU - Aebersold, P. M.

AU - Solomon, D.

AU - Topalian, Suzanne

AU - Toy, S. T.

AU - Simon, P.

AU - Lotze, M. T.

AU - Yang, J. C.

AU - Seipp, C. A.

AU - Simpson, C.

AU - Carter, C.

AU - Bock, S.

AU - Schwartzentruber, D.

AU - Wei, J. P.

AU - White, D. E.

PY - 1988

Y1 - 1988

N2 - Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive tranfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.

AB - Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive tranfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.

UR - http://www.scopus.com/inward/record.url?scp=0024166189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024166189&partnerID=8YFLogxK

M3 - Article

C2 - 3264384

AN - SCOPUS:0024166189

VL - 319

SP - 1676

EP - 1680

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 25

ER -